Immix Biopharma, Inc. announced a class-leading safety profile for sterically-optimized CAR-T NXC-201, including absence of neurotoxicity of any grade in low-volume disease to-date, laying a foundation for potential future indication expansion. NXC-201 interim results, including safety results, were presented at the American Society for Clinical Oncology (ASCO 2025) by Heather Landau, MD of Memorial Sloan Kettering Cancer Center can be accessed on the Company's website under publications (ASCO Postarticle and video, MSKCC article, Cleveland Clinicarticle). A webcast of the Company's Key Opinion Leader (KOL) event to discuss the NXC-201 ASCO 2025 interim results, including safety results.